A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment

G. Schifitto, J. Zhang, S. R. Evans, N. Sacktor, D. Simpson, L. L. Millar, V. L. Hung, E. N. Miller, E. Smith, R. J. Ellis, V. Valcour, E. Singer, C. M. Marra, D. Kolson, J. Weihe, Rory P Remmel, D. Katzenstein, D. B. Clifford, K. Nuffer, S. CahillD. Burgess, K. Carter, M. Shoemaker, A. Weisbeck, N. Hanks, M. Watters, S. A. Chafey, S. Dunaway, M. Perrin, Joseph Quinn, N. Venna, T. Flynn, T. Spitz, M. Gould, B. Cohen, L. Reisberg, R. Diaz-Arrastia, C. Lohner, K. Marder, R. Clouse, D. Mildvan, J. Bailey, K. Tashima, H. Sousa, D. Currin, S. Pedersen

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


BACKGROUND: Cognitive impairment continues to be a significant neurologic complication of HIV infection and has been associated with oxidative stress-induced neuronal injury. Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties. This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance. METHODS: HIV-1 infected individuals with impaired cognitive functioning were enrolled in this placebo-controlled, three-arm study of STS across 17 sites. Cognitive impairment was determined using a standard battery of neuropsychological tests. Subjects were randomized to receive STS 3 mg/24 hours, STS 6 mg/24 hours, or matching placebo patches daily. The primary efficacy endpoint was defined as the change in neuropsychological composite Z-score (NPZ-6) from baseline to week 24. Measures of safety included frequencies of adverse experiences and abnormal results on laboratory tests. RESULTS: A total of 128 subjects (88% men, 51% white) were enrolled, median age 45 years. Most subjects (62%) had mild to moderate AIDS dementia complex. The 24-week NPZ-6 median (interquartile range) changes were 0.22 (-0.28, 0.55) for the selegiline 3 mg/24 hours arm, 0.21 (-0.18, 0.62) for the selegiline 6 mg/24 hours arm, and 0.28 (-0.16, 0.64) for the placebo arm (a positive score indicates improvement from baseline) (p = 0.914). Severe laboratory abnormalities were few and occurred in similar proportion among the three treatment arms. CONCLUSION: Selegiline was safe and well tolerated by HIV-infected individuals with cognitive impairment and mild to moderate immune suppression; however, no cognitive or functional improvement was observed in this phase II study.

Original languageEnglish (US)
Pages (from-to)1314-1321
Number of pages8
Issue number13
StatePublished - Sep 2007

Bibliographical note

Funding Information:
Supported in part by the Adult AIDS Clinical Trials Group funded by NIAID, AI38858, AI38855, AI27670, AI27668, AI27658, AI34853, AI27660, AI27664, A127659, AI25903, AI25915, AI046376-05, AI46370, AI46381, AI50410, AI25868, AI46386, the Neurologic AIDS Research Consortium funded by the National Institute of Neurologic Diseases and Stroke, NS32228, the National Institute of Mental Health, MH64409, and GCRC Units funded by the NCRR, RR00052, RR00044, RR00046. Normative data for cognitive function were collected by the Multicenter AIDS Cohort Study (MACS) with centers (Principal Investigators) at The Johns Hopkins University Bloomberg School of Public Health (Joseph B. Margolick, Alvaro Muñoz), Howard Brown Health Center and Northwestern University Medical School (John Phair), University of California, Los Angeles (Roger Detels, Beth Jamieson), and University of Pittsburgh (Charles Rinaldo, PhD). The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute. UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041.


Dive into the research topics of 'A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment'. Together they form a unique fingerprint.

Cite this